1
|
Kero J, Koivisto JM, Kuusisto A, Kesonen P, Haavisto E. Nursing interventions for dyspnoea management among inpatients with cancer in palliative care. Int J Palliat Nurs 2024; 30:87-98. [PMID: 38407153 DOI: 10.12968/ijpn.2024.30.2.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2024]
Abstract
BACKGROUND Dyspnoea, a commonly reported symptom among patients with cancer, necessitates the need for appropriate non-pharmacological interventions for its management and suitable assessment scales. AIMS To explore the nursing interventions and assessment scales for managing dyspnoea in patients with cancer receiving palliative care. METHODS Systematic review. Five databases (CINAHL Complete, PubMed, Web of Science, Scopus and the Cochrane Central Register of Controlled Trials) were searched, and seven studies were identified. Only studies that comprised randomised controlled trials (RCTs), non-randomised controlled trials or quasi-experimental settings were included. FINDINGS Nursing interventions, that support a patient's physical breathing and mental functioning, are effective in managing dyspnoea. It is crucial to use both subjective and physical assessment methods to accurately measure the outcomes of these interventions. CONCLUSION These interventions have been proven to be effective, with outcomes centred on changes in physiological measurements and patients' subjective expressions.
Collapse
Affiliation(s)
- Johanna Kero
- PhD Candidate, Department of Nursing Science, Tampere University, Tampere, Finland
| | - Jaana-Maija Koivisto
- Associate Professor, Department of Health Science, Tampere University, Tampere, Finland; Faculty of Medicine, University of Helsinki, Finland
| | - Anne Kuusisto
- Postdoctoral Researcher, Department of Nursing Science, University of Turku, Turku, Finland; Wellbeing Services County, Satakunta, Satasairaala Central Hospital Pori, Finland
| | - Pauliina Kesonen
- PhD Candidate, Department of Health Science, Tampere University, Tampere, Finland
| | - Elina Haavisto
- Professor, Department of Health Science, Tampere University, Tampere, Finland; Pirkanmaa Wellbeing Services County, Finland
| |
Collapse
|
2
|
Walsh M, Bowen E, Vaughan C, Kiely F. Heart failure symptom burden in outpatient cardiology: observational cohort study. BMJ Support Palliat Care 2024; 13:e1280-e1284. [PMID: 37076262 DOI: 10.1136/spcare-2023-004167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Accepted: 03/23/2023] [Indexed: 04/21/2023]
Abstract
OBJECTIVES To assess the self-reported symptom burden in patients with a diagnosis of heart failure attending an outpatient cardiology clinic through the utilisation of validated patient-reported outcome measures. METHODS Eligible patients were invited to partake in this observational cohort study. Participant demographics and comorbidities were recorded, followed by participants recording their symptoms using the Integrated Palliative care Outcome Scale (IPOS) and Brief Pain Inventory (BPI) outcome measure tools. RESULTS A total of 22 patients were included in the study. The majority were male (n=15). The median age was 74.5 (range 55-94) years. Atrial fibrillation and hypertension were the most common comorbidities (n=10). Dyspnoea, weakness and poor mobility were the most prevalent symptoms, affecting 15 (68%) of the 22 patients. Dyspnoea was reported as being the most troublesome symptom. The BPI was completed by 68% (n=15) of the study participants. Median average pain score was 5/10; median worst pain score in the preceding 24 hours was 6/10 and median pain score at time of BPI completion was 3/10. The impact of pain on daily living during the preceding 24 hours ranged from impacting on all activities (n=7) to not impacting on activities (n=1). CONCLUSIONS Patients with heart failure experience a range of symptoms that vary in severity. Introduction of a symptom assessment tool in the cardiology outpatient setting could help identify patients with a high symptom burden and prompt timely referral to specialist palliative care services.
Collapse
Affiliation(s)
- Maria Walsh
- Department of Palliative Medicine, Marymount University Hospital and Hospice, Cork, Ireland
| | - Elizabeth Bowen
- Department of Palliative Medicine, Marymount University Hospital and Hospice, Cork, Ireland
| | - Carl Vaughan
- Department of Cardiology, Mercy University Hospital, Cork, Ireland
| | - Fiona Kiely
- Department of Palliative Medicine, Marymount University Hospital and Hospice, Cork, Ireland
| |
Collapse
|
3
|
Beaumont M, Latiers AC, Prieur G. [The role of the physiotherapist in the assessment and management of dyspnea]. Rev Mal Respir 2023; 40:169-187. [PMID: 36682956 DOI: 10.1016/j.rmr.2022.12.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 12/20/2022] [Indexed: 01/21/2023]
Abstract
The role of the physiotherapist in the assessment and management of dyspnea. Dyspnea is the most common symptom in cardio-respiratory diseases. Recently improved comprehension of dyspnea mechanisms have underlined the need for three-faceted assessment. The three key aspects correspond to the "breathing, thinking, functioning" clinical model, which proposes a multidimensional - respiratory, emotional and functional - approach. Before initiating treatment, it is essential for several reasons to assess each specific case, determining the type of dyspnea affecting the patient, appraising the impact of shortness of breath, and estimating the effectiveness of the treatment applied. The physiotherapist has a major role to assume in the care of dyspneic patients, not only in assessment followed by treatment but also as a major collaborator in a multidisciplinary team, especially with regard to pulmonary rehabilitation. The aim of this review is to inventory the existing assessment tools and the possible physiotherapies for dyspnea, using a holistic approach designed to facilitate the choice of techniques and to improve quality of care by fully addressing the patient's needs.
Collapse
Affiliation(s)
- M Beaumont
- Service de réadaptation respiratoire, Centre Hospitalier des Pays de Morlaix, Morlaix, France; Inserm, Univ Brest, CHRU Brest, UMR 1304, GETBO, Brest, France.
| | - A C Latiers
- Service ORL, Stomatologie et Soins Continus, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgique
| | - G Prieur
- Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Groupe de Recherche en Kinésithérapie Respiratoire, Université Catholique de Louvain, 1200 Brussels, Belgique; Université de Normandie, UNIROUEN, EA3830-GRHV, 76000 Rouen, France; Groupe Hospitalier du Havre, Service de pneumologie et de réadaptation respiratoire, avenue Pierre Mendes France, 76290 Montivilliers, France; Institut de Recherche et Innovation en Biomédecine (IRIB), 76000 Rouen, France
| |
Collapse
|
4
|
Pippard B, Bhatnagar M, McNeill L, Donnelly M, Frew K, Aujayeb A. Hepatic Hydrothorax: A Narrative Review. Pulm Ther 2022; 8:241-254. [PMID: 35751800 PMCID: PMC9458779 DOI: 10.1007/s41030-022-00195-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Accepted: 06/01/2022] [Indexed: 12/10/2022] Open
Abstract
Hepatic hydrothorax (HH) represents a distinct clinical entity within the broader classification of pleural effusion that is associated with significant morbidity and mortality. The median survival of patients with cirrhosis who develop HH is 8-12 months. The diagnosis is typically made in the context of advanced liver disease and ascites, in the absence of underlying cardio-pulmonary pathology. A multi-disciplinary approach to management, involving respiratory physicians, hepatologists, and palliative care specialists is crucial to ensuring optimal patient-centered care. However, the majority of accepted therapeutic options are based on expert opinion rather than large, adequately powered randomized controlled trials. In this narrative review, we discuss the epidemiology, pathophysiology, clinical characteristics, and management of HH, highlighting the use of salt restriction and diuretic therapy, porto-systemic shunts, and liver transplantation. We include specific sections focusing on the role of pleural interventions and palliative care, respectively.
Collapse
Affiliation(s)
- Benjamin Pippard
- Department of Respiratory Medicine, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK
| | - Malvika Bhatnagar
- Department of Respiratory Medicine, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK
| | - Lisa McNeill
- Department of Hepatology, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
| | - Mhairi Donnelly
- Department of Hepatology, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
| | - Katie Frew
- Department of Palliative Medicine, Northumbria Healthcare NHS Foundation Trust, North Shields, UK
| | - Avinash Aujayeb
- Department of Respiratory Medicine, Northumbria Healthcare NHS Foundation Trust, North Shields, Northumbria Way, Northumberland, Cramlington, NE23 6NZ, UK.
| |
Collapse
|
5
|
Daynes E. Treating COVID-19-related breathlessness with novel interventions. THE LANCET RESPIRATORY MEDICINE 2022; 10:815-816. [PMID: 35489368 PMCID: PMC9045745 DOI: 10.1016/s2213-2600(22)00161-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Accepted: 04/12/2022] [Indexed: 11/03/2022]
|
6
|
Pyszora A, Lewko A. Non-pharmacological Management in Palliative Care for Patients With Advanced COPD. Front Cardiovasc Med 2022; 9:907664. [PMID: 35924211 PMCID: PMC9339631 DOI: 10.3389/fcvm.2022.907664] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 05/31/2022] [Indexed: 11/13/2022] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is a disabling condition associated with progressive airflow limitation and lung tissue damage; its main symptoms are breathlessness, fatigue, cough, and sputum production. In the advanced stage of the disease, these symptoms may severely impact on a person's physical and psychological functioning, with some also developing chronic respiratory failure, associated with blood gas abnormalities. Non-pharmacological interventions can improve quality of life and functioning in the management of people living with advanced COPD. This article will provide an overview of common non-pharmacological methods used in the symptomatic management of severe COPD, including: breathlessness and fatigue management strategies, anxiety management, pulmonary rehabilitation (PR) and physical activity (PA), neuromuscular electrical stimulation (NMES), airway clearance techniques (ACTs), nutrition and non-invasive ventilation (NIV). The importance of a holistic and multi-disciplinary approach to people living with COPD will be discussed.
Collapse
Affiliation(s)
- Anna Pyszora
- Palliative Care Department, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland
- *Correspondence: Anna Pyszora
| | - Agnieszka Lewko
- Faculty of Health and Life Sciences, Coventry University, Coventry, United Kingdom
| |
Collapse
|
7
|
Hentsch L, Cocetta S, Allali G, Santana I, Eason R, Adam E, Janssens JP. Dificultad respiratoria y COVID-19: Un llamado a la investigación. KOMPASS NEUMOLOGÍA 2022. [PMCID: PMC9059027 DOI: 10.1159/000521663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
La dificultad respiratoria, también conocida como disnea, es un síntoma frecuente que causa debilidad. Varios reportes han destacado la ausencia de disnea en un subgrupo de pacientes que padecen COVID-19, en la llamada hipoxemia «silenciosa» o «feliz». Los reportes también han mencionado la falta de una relación clara entre la gravedad clínica de la enfermedad y los niveles de disnea referidos por los pacientes. Se ha demostrado en gran medida que entre las complicaciones cerebrales del COVID-19 hay alta prevalencia de encefalopatía aguda, que podría afectar el procesamiento de las señales aferentes o bien la modulación descendente de las señales de disnea. En esta revisión pretendemos destacar los mecanismos implicados en la disnea y resumir la fisiopatología del COVID-19 y sus efectos en la interacción cerebro-pulmón. Posteriormente, presentamos hipótesis sobre la alteración de la percepción de la disnea en pacientes con COVID-19 y sugerimos formas de investigar más a fondo este fenómeno.
Collapse
Affiliation(s)
- Lisa Hentsch
- División de Medicina Paliativa, Hospitales de la Universidad de Ginebra, Ginebra, Suiza
- *Lisa Hentsch,
| | | | - Gilles Allali
- División de Neurología, Hospitales de la Universidad de Ginebra y Facultad de Medicina, Universidad de Ginebra, Ginebra, Suiza
- Departamento de Neurología, División de Envejecimiento Cognitivo y Motor, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York, Estados Unidos
| | | | - Rowena Eason
- Phyllis Tuckwell Hospice Care, Surrey, Reino Unido
| | - Emily Adam
- Investigador independiente, Londres, Reino Unido
| | - Jean-Paul Janssens
- División de Enfermedades Pulmonares, Hospital de la Universidad de Ginebra, Ginebra, Suiza
| |
Collapse
|
8
|
Hentsch L, Cocetta S, Allali G, Santana I, Eason R, Adam E, Janssens JP. Atemnot und COVID-19: Ein Aufruf zu mehr Forschung. KOMPASS PNEUMOLOGIE 2022. [PMCID: PMC8805046 DOI: 10.1159/000521460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Atemnot, auch als Dyspnoe bezeichnet, ist ein häufiges und lähmendes Symptom. In mehreren Berichten wurde die Abwesenheit von Atemnot bei einer Untergruppe von Patienten mit COVID-19 hervorgehoben, die manchmal als «stille» oder «glückliche Hypoxie» bezeichnet wird. Ebenfalls wurde in Berichten erwähnt, dass es an einem klaren Zusammenhang zwischen dem klinischen Schweregrad der Erkrankung und der von den Patienten berichteten Schwere der Atemnot fehlt. Die zerebralen Komplikationen von COVID-19 sind weitgehend nachgewiesen, mit einer hohen Prävalenz akuter Enzephalopathien, die möglicherweise die Verarbeitung afferenter Signale oder die absteigende Modulation von Atemnotsignalen beeinträchtigen könnte. In dieser Übersichtsarbeit möchten wir die an der Atemnot beteiligten Mechanismen hervorheben und die Pathophysiologie von COVID-19 und den bekannten Auswirkungen der Erkrankung auf die Interaktion von Gehirn und Lunge zusammenfassen. Anschließend stellen wir Hypothesen für die Veränderung der Wahrnehmung von Atemnot bei COVID-19-Patienten auf und schlagen Möglichkeiten vor, mit denen dieses Phänomen weiter erforscht werden könnte.
Collapse
Affiliation(s)
- Lisa Hentsch
- Abteilung für Pallativmedizin an den Hôpitaux universitaires de Genève, Genf, Schweiz
- *Lisa Hentsch,
| | | | - Gilles Allali
- Abteilung für Neurologie, Hôpitaux universitaires de Genève und Medizinische Fakultät der Universität Genf, Genf, Schweiz
- Division of Cognitive and Motor Aging, Department of Neurology, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York, USA
| | | | - Rowena Eason
- Phyllis Tuckwell Hospice Care, Surrey, Vereinigtes Königreich
| | - Emily Adam
- Unabhängige Forscherin, London, Vereinigtes Königreich
| | - Jean-Paul Janssens
- Abteilung für Lungenkrankheiten, Hôpitaux universitaires de Genève, Genf, Schweiz
| |
Collapse
|
9
|
Lou K. Chronic Obstructive Pulmonary Disease: Emerging Therapies That Can Also Palliate Symptoms #427. J Palliat Med 2021; 24:1895-1896. [PMID: 34851185 DOI: 10.1089/jpm.2021.0408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Long A, Cartwright M, Reilly CC. Impact of fan therapy during exercise on breathlessness and recovery time in patients with COPD: a pilot randomised controlled crossover trial. ERJ Open Res 2021; 7:00211-2021. [PMID: 34760995 PMCID: PMC8573226 DOI: 10.1183/23120541.00211-2021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 08/10/2021] [Indexed: 11/23/2022] Open
Abstract
Background Patients with COPD reduce physical activity to avoid the onset of breathlessness. Fan therapy can reduce breathlessness at rest, but the efficacy of fan therapy during exercise remains unknown in this population. The aim of the present study was to investigate 1) the effect of fan therapy on exercise-induced breathlessness and post-exercise recovery time in patients with COPD and 2) the acceptability of fan therapy during exercise; and 3) to assess the reproducibility of any observed improvements in outcome measures. Methods A pilot single-centre, randomised, controlled, crossover open (nonmasked) trial (clinicaltrials.gov NCT03137524) of fan therapy versus no fan therapy during 6-min walk test (6MWT) in patients with COPD and a modified Medical Research Council (mMRC) dyspnoea score ≥2. Breathlessness intensity was quantified before and on termination of the 6MWT, using the numerical rating scale (NRS) (0–10). Post-exertional recovery time was measured, defined as the time taken to return to baseline NRS breathlessness score. Oxygen saturation and heart rate were measure pre- and post-6MWT. Results 14 patients with COPD completed the trial per protocol (four male, 10 female; median (interquartile range (IQR)) age 66.50 (60.75 to 73.50) years); mMRC dyspnoea 3 (2 to 3)). Fan therapy resulted in lower exercise-induced breathlessness (ΔNRS; Δ modified Borg scale) (within-individual differences in medians (WIDiM) −1.00, IQR −2.00 to −0.50; p<0.01; WIDiM −0.25, IQR −2.00 to 0.00; p=0.02), greater distance walked (metres) during the 6MWT (WIDiM 21.25, IQR 12.75 to 31.88; p<0.01), and improved post-exertional breathlessness (NRS) recovery time (WIDiM −10.00, IQR −78.75 to 50.00; p<0.01). Fan therapy was deemed to be acceptable by 92% of participants. Conclusion Fan therapy was acceptable and provided symptomatic relief to patients with COPD during exercise. These data will inform larger pilot studies and efficacy studies of fan therapy during exercise. Fan therapy was acceptable and provided symptomatic relief to patients with COPD during exercise; these positive preliminary findings suggest that fan therapy merits further investigation in larger and more methodologically rigorous studieshttps://bit.ly/3xR2GDW
Collapse
Affiliation(s)
- Alex Long
- Dept of Physiotherapy, King's College Hospital NHS Foundation Trust, London, UK.,School of Health Sciences, City, University of London, London, UK
| | | | - Charles C Reilly
- Dept of Physiotherapy, King's College Hospital NHS Foundation Trust, London, UK.,Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's College London, London, UK
| |
Collapse
|
11
|
Hentsch L, Cocetta S, Allali G, Santana I, Eason R, Adam E, Janssens JP. Breathlessness and COVID-19: A Call for Research. Respiration 2021; 100:1016-1026. [PMID: 34333497 PMCID: PMC8450822 DOI: 10.1159/000517400] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Accepted: 05/19/2021] [Indexed: 01/08/2023] Open
Abstract
Breathlessness, also known as dyspnoea, is a debilitating and frequent symptom. Several reports have highlighted the lack of dyspnoea in a subgroup of patients suffering from COVID-19, sometimes referred to as “silent” or “happy hypoxaemia.” Reports have also mentioned the absence of a clear relationship between the clinical severity of the disease and levels of breathlessness reported by patients. The cerebral complications of COVID-19 have been largely demonstrated with a high prevalence of an acute encephalopathy that could possibly affect the processing of afferent signals or top-down modulation of breathlessness signals. In this review, we aim to highlight the mechanisms involved in breathlessness and summarize the pathophysiology of COVID-19 and its known effects on the brain-lung interaction. We then offer hypotheses for the alteration of breathlessness perception in COVID-19 patients and suggest ways of further researching this phenomenon.
Collapse
Affiliation(s)
- Lisa Hentsch
- Division of Palliative Medicine, Geneva University Hospitals, Geneva, Switzerland
| | | | - Gilles Allali
- Division of Neurology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.,Division of Cognitive and Motor Aging, Department of Neurology, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York, USA
| | | | - Rowena Eason
- Phyllis Tuckwell Hospice Care, Surrey, United Kingdom
| | - Emily Adam
- Independent Researcher, London, United Kingdom
| | - Jean-Paul Janssens
- Division of Pulmonary Diseases, Geneva University Hospital, Geneva, Switzerland
| |
Collapse
|
12
|
Banzett RBB, Sheridan AR, Baker KM, Lansing RW, Stevens JP. 'Scared to death' dyspnoea from the hospitalised patient's perspective. BMJ Open Respir Res 2021; 7:7/1/e000493. [PMID: 32169831 PMCID: PMC7069254 DOI: 10.1136/bmjresp-2019-000493] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 10/22/2019] [Accepted: 12/05/2019] [Indexed: 11/04/2022] Open
Abstract
Because dyspnoea is seldom experienced by healthy people, it can be hard for clinicians and researchers to comprehend the patient’s experience. We collected patients’ descriptions of dyspnoea in their own words during a parent study in which 156 hospitalised patients completed a quantitative multidimensional dyspnoea questionnaire. These volunteered comments describe the severity and wide range of experiences associated with dyspnoea and its impacts on a patients’ life. They provide insights not conveyed by structured rating scales. We organised these comments into the most prominent themes, which included sensory experiences, emotional responses, self-blame and precipitating events. Patients often mentioned air hunger (‘Not being able to get air is the worst thing that could ever happen to you.’), anxiety, and fear (‘Scared. I thought the world was going to end, like in a box.’). Their value in patient care is suggested by one subject’s comment: ‘They should have doctors experience these symptoms, especially dyspnoea, so they understand what patients are going through.’ Patients’ own words can help to bridge this gap of understanding.
Collapse
Affiliation(s)
- Robert B B Banzett
- Pulmonary, Critical Care, and Sleep Medicine, and Department of Nursing, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA .,Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
| | - Andrew R Sheridan
- Pulmonary, Critical Care, and Sleep Medicine, and Department of Nursing, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Kathy M Baker
- Nursing, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Robert W Lansing
- Pulmonary, Critical Care, and Sleep Medicine, and Department of Nursing, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Jennifer P Stevens
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.,Pulmonary, Critical Care, and Sleep Medicine; Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| |
Collapse
|
13
|
Khor YH, Saravanan K, Holland AE, Lee JYT, Ryerson CJ, McDonald CF, Goh NSL. A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease. Sci Rep 2021; 11:6874. [PMID: 33767311 PMCID: PMC7994303 DOI: 10.1038/s41598-021-86326-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 03/15/2021] [Indexed: 11/26/2022] Open
Abstract
Dyspnoea is a cardinal symptom of fibrotic interstitial lung disease (ILD), with a lack of proven effective therapies. With emerging evidence of the role of facial and nasal airflow for relieving breathlessness, this pilot study was conducted to examine the feasibility of conducting a clinical trial of a handheld fan (HHF) for dyspnoea management in patients with fibrotic ILD. In this mixed-methods, randomised, assessor-blinded, controlled trial, 30 participants with fibrotic ILD who were dyspnoeic with a modified Medical Research Council Dyspnoea grade ≥ 2 were randomised to a HHF for symptom control or no intervention for 2 weeks. Primary outcomes were trial feasibility, change in Dyspnoea-12 scores at Week 2, and participants’ perspectives on using a HHF for dyspnoea management. Study recruitment was completed within nine months at a single site. Successful assessor blinding was achieved in the fan group [Bang’s Blinding Index − 0.08 (95% CI − 0.45, 0.30)] but not the control group [0.47 (0.12, 0.81)]. There were no significant between-group differences for the change in Dyspnoea-12 or secondary efficacy outcomes. During qualitative interviews, participants reported that using the HHF relieved breathlessness and provided relaxation, despite initial scepticism about its therapeutic benefit. Oxygen-experienced participants described the HHF being easier to use, but not as effective for symptomatic relief, compared to oxygen therapy. Our results confirmed the feasibility of a clinical trial of a HHF in fibrotic ILD. There was a high level of patient acceptance of a HHF for managing dyspnoea, with patients reporting both symptomatic benefits and ease of use.
Collapse
Affiliation(s)
- Yet H Khor
- Department of Respiratory and Sleep Medicine, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia. .,Institute for Breathing and Sleep, Heidelberg, VIC, Australia. .,Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia. .,Department of Respiratory Medicine, Alfred Health, Melbourne, Australia.
| | | | - Anne E Holland
- Institute for Breathing and Sleep, Heidelberg, VIC, Australia.,Department of Allergy, Immunology and Respiratory Medicine, Monash University, Melbourne, Australia.,Department of Physiotherapy, Alfred Health, Melbourne, Australia
| | - Joanna Y T Lee
- Department of Allergy, Immunology and Respiratory Medicine, Monash University, Melbourne, Australia
| | - Christopher J Ryerson
- Centre for Heart Lung Innovation, Providence Health Care, Vancouver, BC, Canada.,Department of Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Christine F McDonald
- Department of Respiratory and Sleep Medicine, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia.,Institute for Breathing and Sleep, Heidelberg, VIC, Australia.,Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia
| | - Nicole S L Goh
- Department of Respiratory and Sleep Medicine, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia.,Institute for Breathing and Sleep, Heidelberg, VIC, Australia.,Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia.,Department of Respiratory Medicine, Alfred Health, Melbourne, Australia
| |
Collapse
|
14
|
Abstract
Dyspnea is a symptom commonly experienced by cancer patients that causes significant suffering, worsens throughout a patient's disease trajectory, and can be more difficult to manage than other symptoms. Assessment of dyspnea is best accomplished by a subjective description; physiologic measures are only weakly correlated with the patient's experience. It is important to consider a wide range of possible malignant and nonmalignant causes of dyspnea in cancer patients and to correct underlying causes where possible. For patients with refractory dyspnea, opioids are a safe and effective treatment. Benzodiazepines can be considered, but the evidence for their use is weak. Supplemental oxygen is beneficial if patients are hypoxemic, or if they have concurrent chronic obstructive pulmonary disease. Nonpharmacologic strategies such as fan therapy, exercise programs, and pulmonary rehabilitation can also be beneficial. One important diagnosis to consider in all cancer patients is venous thromboembolism. Prompt evaluation and treatment are vital to improving symptoms and outcomes for patients. Although dyspnea is common and potentially debilitating in cancer patients, it can be effectively managed with a structured approach to rule out reversible causes while concurrently treating the patient using appropriate therapeutic strategies.
Collapse
Affiliation(s)
- A M Crombeen
- Department of Family Medicine, Western University, London, ON
| | - E J Lilly
- Department of Family Medicine, Western University, London, ON
| |
Collapse
|
15
|
Asano R, Newton PJ, Currow DC, Macdonald PS, Leung D, Phillips JL, Perrin N, Davidson PM. Rationale for targeted self-management strategies for breathlessness in heart failure. Heart Fail Rev 2019; 26:71-79. [PMID: 31873843 DOI: 10.1007/s10741-019-09907-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
To provide a conceptual rationale for targeted self-management strategies for breathlessness in chronic heart failure. Breathlessness is a defining symptom of chronic heart failure and is the primary cause for hospital readmissions and emergency room visits, resulting in extensive health care utilization. Chronic breathlessness, punctuated by acute physiological decompensation, is a sentinel symptom of the heart failure syndrome and often intensifies towards the end of life. Drawing upon evidence-based guidelines, physiological mechanisms and existing conceptual models for the management of breathlessness is proposed. Key elements of this model include adherence to evidence-based approaches (pharmacological and non-pharmacological management to optimize heart failure treatment), self-monitoring of symptoms, identification of modifiable factors (such as fluid overload), and targeted strategies for breathlessness including distraction and gas flow. Self-management is an essential component in heart failure management which could positively influences health outcomes and quality of life. Refining programs to focus on breathlessness may have the potential to reduce symptom burden and improve quality of life.
Collapse
Affiliation(s)
- Reiko Asano
- Johns Hopkins University School of Nursing, 525 N. Wolfe Street, Baltimore, MD, USA.
- Georgetown University School of Nursing & Health Studies, Washington, DC, USA.
| | - Phillip J Newton
- Western Sydney University School of Nursing and Midwifery, Sydney, Australia
| | - David C Currow
- Faculty of Health, University of Technology Sydney, Sydney, Australia
| | | | | | - Jane L Phillips
- Faculty of Health, University of Technology Sydney, Sydney, Australia
| | - Nancy Perrin
- Johns Hopkins University School of Nursing, 525 N. Wolfe Street, Baltimore, MD, USA
| | - Patricia M Davidson
- Johns Hopkins University School of Nursing, 525 N. Wolfe Street, Baltimore, MD, USA
- Faculty of Health, University of Technology Sydney, Sydney, Australia
| |
Collapse
|
16
|
Watson JS. Non-pharmacological management of chronic breathlessness in stable chronic obstructive pulmonary disease. Br J Community Nurs 2019; 23:376-381. [PMID: 30063393 DOI: 10.12968/bjcn.2018.23.8.376] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
This paper will review and address the pathological processes in chronic obstructive pulmonary disease (COPD), including the prevalence of comorbidities and the implications of these factors for a common disabling COPD symptom, breathlessness. It will further consider non-pharmacological strategies that community nurses can use to support breathlessness relief in the context of holistic patient care.
Collapse
Affiliation(s)
- Jane S Watson
- Senior Lecturer in Community Nursing, School of Nursing and Midwifery, Anglia Ruskin University
| |
Collapse
|
17
|
Sime C, Milligan S, Rooney KD. Improving the waiting times within a hospice breathlessness service. BMJ Open Qual 2019; 8:e000582. [PMID: 31206064 PMCID: PMC6542418 DOI: 10.1136/bmjoq-2018-000582] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 11/20/2018] [Indexed: 12/03/2022] Open
Abstract
Background Breathlessness, a common symptom in advanced disease, is a distressing, complex symptom that can profoundly affect the quality of one’s life. Evidence suggests that specialist palliative care breathlessness intervention services can improve physical well-being, personal coping strategies and quality of life. In the UK, the use of quality improvement methods is well documented in the National Health Service. However, within the independent hospice sector there is a lack of published evidence of using such methods to improve service provision. Aim The aim of this project was to reduce the waiting time from referral to service commencement for a hospice breathlessness service by 40%—from a median of 19.5 to 11.5 working days. Methods Using a quality planning and systems thinking approach staff identified barriers and blockages in the current system and undertook plan-do-study-act cycles to test change ideas. The ideas tested included offering home visits to patients on long-term oxygen, using weekly team ‘huddles’, streamlining the internal referral process and reallocating staff resources. Results Using quality improvement methods enabled staff to proactively engage in positive changes to improve the service provided to people living with chronic breathlessness. Offering alternatives to morning appointments; using staff time more efficiently and introducing accurate data collection enabled staff to monitor waiting times in real time. The reduction achieved in the median waiting time from referral to service commencement exceeded the project aim. Conclusions This project demonstrates that quality improvement methodologies can be successfully used in a hospice setting to improve waiting times and meet the specific needs of people receiving specialist palliative care.
Collapse
Affiliation(s)
- Caroline Sime
- Institute for Research in Healthcare Policy & Practice, University of the West of Scotland, Hamilton, Scotland
| | - Stuart Milligan
- School of Health and Life Sciences, University of the West of Scotland, Paisley, Scotland
| | - Kevin Donal Rooney
- School of Health and Life Sciences, University of the West of Scotland, Paisley, Scotland.,Consultant in Anaesthesia and Intensive Care Medicine, Royal Alexandra Hospital, Paisley, Professor of Care Improvement, University of the West of Scotland, Hamilton, Scotland
| |
Collapse
|
18
|
Haywood A, Duc J, Good P, Khan S, Rickett K, Vayne-Bossert P, Hardy JR. Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. Cochrane Database Syst Rev 2019; 2:CD012704. [PMID: 30784058 PMCID: PMC6381295 DOI: 10.1002/14651858.cd012704.pub2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
BACKGROUND Dyspnoea is a common symptom in advanced cancer, with a prevalence of up to 70% among patients at end of life. The cause of dyspnoea is often multifactorial, and may cause considerable psychological distress and suffering. Dyspnoea is often undertreated and good symptom control is less frequently achieved in people with dyspnoea than in people with other symptoms of advanced cancer, such as pain and nausea. The exact mechanism of action of corticosteroids in managing dyspnoea is unclear, yet corticosteroids are commonly used in palliative care for a variety of non-specific indications, including pain, nausea, anorexia, fatigue and low mood, despite being associated with a wide range of adverse effects. In view of their widespread use, it is important to seek evidence of the effects of corticosteroids for the management of cancer-related dyspnoea. OBJECTIVES To assess the effects of systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. SEARCH METHODS We searched CENTRAL, MEDLINE, Embase, CINAHL, Science Citation Index Web of Science, Latin America and Caribbean Health Sciences (LILACS) and clinical trial registries, from inception to 25 January 2018. SELECTION CRITERIA We included randomised controlled trials that included adults aged 18 years and above. We included participants with cancer-related dyspnoea when randomised to systemic corticosteroids (at any dose) administered for the relief of cancer-related dyspnoea or any other indication, compared to placebo, standard or alternative treatment. DATA COLLECTION AND ANALYSIS Five review authors independently assessed trial quality and three extracted data. We used means and standard deviations for each outcome to report the mean difference (MD) with 95% confidence interval (CI). We assessed the risk of bias and quality of evidence using GRADE. We extracted primary outcomes of sensory-perceptual experience of dyspnoea (intensity of dyspnoea), affective distress (quality of dyspnoea) and symptom impact (burden of dyspnoea or impact on function) and secondary outcomes of serious adverse events, participant satisfaction with treatment and participant withdrawal from trial. MAIN RESULTS Two studies met the inclusion criteria, enrolling 157 participants (37 participants in one study and 120 in the other study), of whom 114 were included in the analyses. The studies compared oral dexamethasone to placebo, followed by an open-label phase in one study. One study lasted seven days, and the duration of the other study was 15 days.We were unable to conduct many of our predetermined analyses due to different agents, dosages, comparators and outcome measures, routes of drug delivery, measurement scales and time points. Subgroup analysis according to type of cancer was not possible.Primary outcomesWe included two studies (114 participants) with data at one week in the meta-analysis for change in dyspnoea intensity/dyspnoea relief from baseline. Corticosteroid therapy with dexamethasone resulted in an MD of lower dyspnoea intensity compared to placebo at one week (MD -0.85 lower dyspnoea (scale 0-10; lower score = less breathlessness), 95% CI -1.73 to 0.03; very low-quality evidence), although we were uncertain as to whether corticosteroids had an important effect on dyspnoea as results were imprecise. We downgraded the quality of evidence by three levels from high to very low due to very serious study limitations and imprecision.One study measured affective distress (quality of dyspnoea) and results were similar between groups (29 participants; very low-quality evidence). We downgraded the quality of the evidence three times for imprecision, inconsistency, and serious study limitations.Both studies assessed symptom impact (burden of dyspnoea or impact on function) (113 participants; very low-quality evidence). In one study, it was unclear whether dexamethasone had an effect on dyspnoea as results were imprecise. The second study showed more improvement for physical well-being scores at days eight and 15 in the dexamethasone group compared with the control group, but there was no evidence of a difference for FACIT social/family, emotional or functional scales. We downgraded the quality of the evidence three times for imprecision, inconsistency, and serious study limitations.Secondary outcomesDue to the lack of homogenous outcome measures and inconsistency in reporting, we could not perform quantitative analysis for any secondary outcomes. In both studies, the frequency of adverse events was similar between groups, and corticosteroids were generally well tolerated. The withdrawal rates for the two studies were 15% and 36%. Reasons for withdrawal included lost to follow-up, participant or carer (or both) refusal, and death due to disease progression. We downgraded the quality of evidence for these secondary outcomes by three levels from high to very low due to serious study limitations, inconsistency and imprecision.Neither study examined participant satisfaction with treatment. AUTHORS' CONCLUSIONS There are few studies assessing the effects of systemic corticosteroids on cancer-related dyspnoea in adults with cancer. We judged the evidence to be of very low quality that neither supported nor refuted corticosteroid use in this population. Further high-quality studies are needed to determine if corticosteroids are efficacious in this setting.
Collapse
Affiliation(s)
- Alison Haywood
- School of Pharmacy, Menzies Health Institute Queensland, Griffith University, Gold Coast, Australia
| | | | | | | | | | | | | |
Collapse
|
19
|
Tieck K, Mackenzie L, Lovell M. The lived experience of refractory breathlessness for people living in the community. Br J Occup Ther 2018. [DOI: 10.1177/0308022618804754] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Kezia Tieck
- Occupational therapist, MOT graduate, Discipline of Occupational Therapy, University of Sydney, Australia
| | - Lynette Mackenzie
- Associate Professor, Discipline of Occupational Therapy, University of Sydney, Australia
| | - Melanie Lovell
- Staff Specialist, Palliative Care, Greenwich Hospital, Sydney, Australia
| |
Collapse
|
20
|
Assayag D, Camp PG, Fisher J, Johannson KA, Kolb M, Lohmann T, Manganas H, Morisset J, Ryerson CJ, Shapera S, Simon J, Singer LG, Fell CD. Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. CANADIAN JOURNAL OF RESPIRATORY CRITICAL CARE AND SLEEP MEDICINE 2018. [DOI: 10.1080/24745332.2018.1503456] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Deborah Assayag
- Department of Medicine, McGill University, Montreal, Quebec, Canada
| | - Pat G. Camp
- Department of Physical Therapy & the Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada
| | - Jolene Fisher
- Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada
| | | | - Martin Kolb
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Tara Lohmann
- Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Helene Manganas
- Department of Medicine, Université de Montréal, Montreal, Quebec, Canada
| | - Julie Morisset
- Department of Medicine, Université de Montréal, Montreal, Quebec, Canada
| | - Christopher J. Ryerson
- Department of Medicine, University of British Columbia and St Paul's Hospital, Vancouver, British Columbia, Canada
| | - Shane Shapera
- Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada
| | - Jessica Simon
- Department of Oncology, University of Calgary, Calgary, Alberta, Canada
| | - Lianne G. Singer
- Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada
| | - Charlene D. Fell
- Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
21
|
Stowe E, Wagland R. A qualitative exploration of distress associated with episodic breathlessness in advanced lung cancer. Eur J Oncol Nurs 2018; 34:76-81. [PMID: 29784142 DOI: 10.1016/j.ejon.2018.03.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Revised: 03/22/2018] [Accepted: 03/26/2018] [Indexed: 11/18/2022]
Abstract
PURPOSE Breathlessness is a distressing symptom, particularly common in those with advanced lung cancer. Previous research has identified the symptom occurrence of episodic breathlessness, identifying average frequency, duration and severity of episodes, but has not explored the distress specifically associated with these episodes. This study explored the distress associated with episodic breathlessness for adults with advanced cancer and the relative impact of three elements; frequency, duration or severity. METHODS Semi-structured interviews were conducted with four participants with advanced lung cancer. Analysis adopted an interpretative phenomenological approach. RESULTS A complex relationship existed between distress caused by episodic breathlessness and its frequency, duration and severity for study participants. Episodic breathlessness had a significant impact on participant's perceptions of self and previous experience effected how distressed they were by their breathlessness. The emotional work created by the symptom was considerable for individuals. CONCLUSION The study highlights the importance of recognizing symptoms as a combination of different experiences that may each cause different levels of distress. Initial evidence is provided that the emotional work involved for patients to self-manage each separate element of breathlessness should be considered in its treatment.
Collapse
Affiliation(s)
- Emily Stowe
- St Clare Hospice, Hastingwood Road, Hastingwood, Essex, CM17 9JX, United Kingdom.
| | - Richard Wagland
- Faculty of Health Sciences, Building 67, Highfield, University of Southampton, SO17 1BJ, United Kingdom.
| |
Collapse
|
22
|
Abstract
PURPOSE OF REVIEW Chronic breathlessness is common in patients with advanced illness who require palliative care. Achieving good symptom control can be challenging. More people with advanced illness live in low and middle income than in high-income countries, but they are much less likely to receive palliative care. Most of the emerging evidence for the palliative management of chronic breathlessness is from high-income countries. This review explores the context of chronic breathlessness in low-income settings, how evidence for control of chronic breathlessness might relate to these settings and where further work should be focused. RECENT FINDINGS Systems for control of noncommunicable diseases (NCDs) in these low-income contexts are poorly developed and health services are often overwhelmed with high levels both of NCD and communicable disease. Multidisciplinary and holistic approaches to disease management are often lacking in these settings. Developing an integrated primary care approach to NCD management is increasingly recognized as a key strategy and this should include palliative care. Most evidence-based approaches to the control of chronic breathlessness could be adapted for use in these contexts SUMMARY: Hand held fans, breathing techniques, graded exercise and use of low-dose morphine can all be used in low-income settings particularly in the context of holistic care. Research is needed into the most effective ways of implementing such interventions and palliative care needs to be promoted as a fundamental aspect of NCD management.
Collapse
|
23
|
Maddocks M, Lovell N, Booth S, Man WDC, Higginson IJ. Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease. Lancet 2017; 390:988-1002. [PMID: 28872031 DOI: 10.1016/s0140-6736(17)32127-x] [Citation(s) in RCA: 127] [Impact Index Per Article: 18.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Revised: 06/29/2017] [Accepted: 07/07/2017] [Indexed: 12/30/2022]
Abstract
People with advanced chronic obstructive pulmonary disease (COPD) have distressing physical and psychological symptoms, often have limited understanding of their disease, and infrequently discuss end-of-life issues in routine clinical care. These are strong indicators for expert multidisciplinary palliative care, which incorporates assessment and management of symptoms and concerns, patient and caregiver education, and sensitive communication to elicit preferences for care towards the end of life. The unpredictable course of COPD and the difficulty of predicting survival are barriers to timely referral and receipt of palliative care. Early integration of palliative care with respiratory, primary care, and rehabilitation services, with referral on the basis of the complexity of symptoms and concerns, rather than prognosis, can improve patient and caregiver outcomes. Models of integrated working in COPD could include: services triggered by troublesome symptoms such as refractory breathlessness; short-term palliative care; and, in settings with limited access to palliative care, consultation only in specific circumstances or for the most complex patients.
Collapse
Affiliation(s)
- Matthew Maddocks
- Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King's College London, London, UK
| | - Natasha Lovell
- Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King's College London, London, UK
| | - Sara Booth
- Department of Palliative Medicine, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Oncology, University of Cambridge, Cambridge, UK
| | - William D-C Man
- Harefield Pulmonary Rehabilitation and Muscle Research Laboratory, Harefield Hospital, Royal Brompton & Harefield NHS Foundation Trust, London, UK
| | - Irene J Higginson
- Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King's College London, London, UK.
| |
Collapse
|
24
|
Haywood A, Duc J, Good P, Khan S, Rickett K, Vayne-Bossert P, Hardy JR. Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. Hippokratia 2017. [DOI: 10.1002/14651858.cd012704] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Alison Haywood
- School of Pharmacy, Menzies Health Institute Queensland, Griffith University; Gold Coast Australia
- Mater Research Institute - The University of Queensland; Brisbane Australia
| | - Jacqueline Duc
- Mater Health Services; Department of Palliative and Supportive Care; Brisbane Australia
- Faculty of Medicine; University of Brisbane Brisbane Australia
- Children's Health Queensland; Paediatric Palliative Care Service; Brisbane Australia
| | - Phillip Good
- Mater Research Institute - The University of Queensland; Brisbane Australia
- Mater Health Services; Department of Palliative and Supportive Care; Brisbane Australia
- St Vincent's Private Hospital; Department of Palliative Care; 411 Main Street Kangaroo Point Brisbane Queensland Australia 4169
| | - Sohil Khan
- School of Pharmacy, Menzies Health Institute Queensland, Griffith University; Gold Coast Australia
- Mater Research Institute - The University of Queensland; Brisbane Australia
| | - Kirsty Rickett
- UQ/Mater McAuley Library; The University of Queensland Library; Raymond Terrace Brisbane Queensland Australia 4101
| | - Petra Vayne-Bossert
- University Hospitals of Geneva; Department of Readaptation and Palliative Medicine; 11 chemin de la Savonnière Collonge-Bellerive Geneva Switzerland 1245
| | - Janet R Hardy
- Mater Research Institute - The University of Queensland; Brisbane Australia
- Mater Health Services; Department of Palliative and Supportive Care; Brisbane Australia
| |
Collapse
|
25
|
Bolzani A, Rolser SM, Kalies H, Maddocks M, Rehfuess E, Gysels M, Higginson IJ, Booth S, Bausewein C. Physical interventions for breathlessness in adults with advanced diseases. Hippokratia 2017. [DOI: 10.1002/14651858.cd012684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Anna Bolzani
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| | - Stefanie M Rolser
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| | - Helen Kalies
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| | - Matthew Maddocks
- Cicely Saunders Institute, King's College London; Department of Palliative Care, Policy and Rehabilitation; Denmark Hill London UK SE5 9PJ
| | - Eva Rehfuess
- LMU Munich; Institute for Medical Informatics, Biometry and Epidemiology, Pettenkofer School of Public Health; Marchioninistr. 15 Munich Germany 81377
| | - Marjolein Gysels
- University of Amsterdam; Amsterdam Institute of Social Science Research; Amsterdam Netherlands
| | - Irene J Higginson
- King's College London; Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute; Bessemer Road Denmark Hill London UK SE5 9PJ
| | - Sara Booth
- Cambridge University Hospitals; Department of Palliative Care; Cambridge UK
| | - Claudia Bausewein
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| |
Collapse
|
26
|
Bolzani A, Rolser SM, Kalies H, Maddocks M, Rehfuess E, Swan F, Gysels M, Higginson IJ, Booth S, Bausewein C. Respiratory interventions for breathlessness in adults with advanced diseases. THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2017. [DOI: 10.1002/14651858.cd012683] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Anna Bolzani
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| | - Stefanie M Rolser
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| | - Helen Kalies
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| | - Matthew Maddocks
- Cicely Saunders Institute, King's College London; Department of Palliative Care, Policy and Rehabilitation; Denmark Hill London UK SE5 9PJ
| | - Eva Rehfuess
- LMU Munich; Institute for Medical Informatics, Biometry and Epidemiology, Pettenkofer School of Public Health; Marchioninistr. 15 Munich Germany 81377
| | - Flavia Swan
- University of Hull; Hull Medical School; Hull UK
| | - Marjolein Gysels
- University of Amsterdam; Amsterdam Institute of Social Science Research; Amsterdam Netherlands
| | - Irene J Higginson
- King's College London; Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute; Bessemer Road Denmark Hill London UK SE5 9PJ
| | - Sara Booth
- Cambridge University Hospitals; Department of Palliative Care; Cambridge UK
| | - Claudia Bausewein
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| |
Collapse
|
27
|
Bolzani A, Rolser SM, Kalies H, Maddocks M, Rehfuess E, Hutchinson A, Gysels M, Higginson IJ, Booth S, Bausewein C. Cognitive-emotional interventions for breathlessness in adults with advanced diseases. Hippokratia 2017. [DOI: 10.1002/14651858.cd012682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Anna Bolzani
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| | - Stefanie M Rolser
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| | - Helen Kalies
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| | - Matthew Maddocks
- Cicely Saunders Institute, King's College London; Department of Palliative Care, Policy and Rehabilitation; Denmark Hill London UK SE5 9PJ
| | - Eva Rehfuess
- LMU Munich; Institute for Medical Informatics, Biometry and Epidemiology, Pettenkofer School of Public Health; Marchioninistr. 15 Munich Germany 81377
| | | | - Marjolein Gysels
- University of Amsterdam; Amsterdam Institute of Social Science Research; Amsterdam Netherlands
| | - Irene J Higginson
- King's College London; Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute; Bessemer Road Denmark Hill London UK SE5 9PJ
| | - Sara Booth
- Cambridge University Hospitals; Department of Palliative Care; Cambridge UK
| | - Claudia Bausewein
- LMU Munich; Department of Palliative Medicine, Munich University Hospital; Marchioninistr. 15 Munich Germany
| |
Collapse
|
28
|
Breathing SPACE-a practical approach to the breathless patient. NPJ Prim Care Respir Med 2017; 27:5. [PMID: 28138132 PMCID: PMC5434774 DOI: 10.1038/s41533-016-0006-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Revised: 11/28/2016] [Accepted: 12/02/2016] [Indexed: 11/16/2022] Open
Abstract
Breathlessness is a common symptom that may have multiple causes in any one individual and causes that may change over time. Breathlessness campaigns encourage people to see their General Practitioner if they are unduly breathless. Members of the London Respiratory Network collaborated to develop a tool that would encourage a holistic approach to breathlessness, which was applicable both at the time of diagnosis and during ongoing management. This has led to the development of the aide memoire “Breathing SPACE”, which encompasses five key themes—smoking, pulmonary disease, anxiety/psychosocial factors, cardiac disease, and exercise/fitness. A particular concern was to ensure that high-value interventions (smoking cessation and exercise interventions) are prioritised across the life-course and throughout the course of disease management. The approach is relevant both to well people and in those with an underling diagnosis or diagnoses. The inclusion of anxiety draws attention to the importance of mental health issues. Parity of esteem requires the physical health problems of people with mental illness to be addressed. The SPACE mnemonic also addresses the problem of underdiagnosis of heart disease in people with lung disease and vice versa, as well as the systematic undertreatment of these conditions where they do co-occur.
Collapse
|
29
|
Whitburn T, Selman LE. Palliative care series: an overview. Postgrad Med J 2016; 93:307. [DOI: 10.1136/postgradmedj-2016-134710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Accepted: 12/02/2016] [Indexed: 11/04/2022]
|
30
|
Bausewein C. [Management of refractory breathlessness in patients with advanced disease]. Internist (Berl) 2016; 57:978-982. [PMID: 27587195 DOI: 10.1007/s00108-016-0122-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Breathlessness is a frequent and distressing symptom in advanced disease. It can have a significant impact on the quality of life of both patients and relatives. OBJECTIVES A summary of nonpharmacological and pharmacological measures for breathlessness based on existing evidence is provided. MATERIALS AND METHODS Analysis of primary studies, reviews and guidelines for the named symptoms and their management were analyzed. RESULTS Recognition and assessment are essential for the management of breathlessness. Management includes various nonpharmacological and pharmacological measures, which should be combined for best results. Nonpharmacological strategies comprise general information, management plan, hand-held fan, physical activity, and rollators. Opioids are the drugs of choice for intractable breathlessness. The evidence base for benzodiazepines and other drugs is rather weak. CONCLUSION A number of treatment options, especially in the nonpharmacological area, help the patients to better cope with their breathlessness.
Collapse
Affiliation(s)
- C Bausewein
- Klinik und Poliklinik für Palliativmedizin, Klinikum der Universität München, Marchioninistr. 15, 81377, München, Deutschland.
| |
Collapse
|